ClinicalTrials.gg
CompletedNCT02504268AVERT-2Updated Jun 28, 2021Results posted

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 201 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-28.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
994
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
6th of 63
994 · median 119
Started
2015
with 2 others
Phase 3
26 of 63
2 open now
Registered
43rd of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 26 in phase 3, and was the 43rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.

Read the detailed description

Subcutaneous (SC)

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Rheumatoid arthritis (RA) diagnosis less than 6 months
  • CRP > 3 mg/L or Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/h
  • At least 3 swollen and 3 tender joints
  • Anti-citrullinated protein antibodies (ACPA) positive

Exclusion criteria

Exclusion Criteria:

  • At risk for tuberculosis
  • Have acute infection
  • Have chronic or recurrent bacterial or serious latent viral infection
  • History of in the last 5 years except squamous skin, basal skin or cervical carcinoma
  • Previous treatment with any conventional or biologic Disease-modifying anti rheumatic drugs (DMARD)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
994 participants (actual)

Study arms

  • Experimental
    Combination Therapy: Abatacept + Methotrexate

    Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week

    Drug: Abatacept · Drug: Methotrexate

  • Active comparator
    Methotrexate treatment

    Methotrexate at least 15mg per week tablet or capsule orally

    Drug: Methotrexate

  • Placebo comparator
    Abatacept Placebo

    Placebo for Abatacept subcutaneous injection once per week

    Other: Abatacept Placebo

  • Placebo comparator
    Methotrexate Placebo

    Placebo to match Methotrexate capsule orally once per week

    Other: Methotrexate Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24

    Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24

    DAS28-CRP = Disease Activity Score 28 based on C-reactive protein DAS28-CRP Remission is defined as DAS28-CRP \<= 2.6 Using a logistic regression model that includes treatment arm, stratification variable and baseline measure as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided.

    Time frame: Week 24

  2. Percentage of Participants in SDAI Remission at Week 52

    Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.

    Time frame: Week 52

  3. Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52

    The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage. The mean change from baseline in TSS using modified Sharp/van der Heijide scores was assessed using a rank-based nonparametric ANCOVA model.

    Time frame: Week 52

  4. Percentage of Participants in Boolean Remission at Week 52

    Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale). Logistic regression was used for this endpoint.

    Time frame: Week 52

07

Results

Posted Apr 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Started451301242000000
Induction to open label289196147000000
Early escaped to open label10218000000
Induction to de-escalation943753000000
Randomized in de-escalation period0005050473700
De-escalation to open label extension0003630322200
Early escaped de-escalation to open label period000254300
Open label and open label extension period0000000685120
Completed388233201000000
Not completed636841000000
Withdrew: Adverse event18814000000
Withdrew: Withdrawal of consent11103000000
Withdrew: Pregnancy200000000
Withdrew: Lost to follow-up364000000
Withdrew: Death110000000
Withdrew: Subject request to discontinue1136000000
Withdrew: No longer meets study criteria230000000
Withdrew: Lack of efficacy11359000000
Withdrew: Poor/non-compliance323000000
Withdrew: Not disclosed102000000

Outcome measures

PrimaryPercentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24

Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24
Percentage of participantsCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 2421.3 (16.0 to 26.7)16.0 (10.1 to 21.9)———————
Statistical analysis
  • Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) vs Placebo + Methotrexate (Cohort 1, IP) · Regression, Logistic · p = 0.2359
SecondaryPercentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24

DAS28-CRP = Disease Activity Score 28 based on C-reactive protein DAS28-CRP Remission is defined as DAS28-CRP \<= 2.6 Using a logistic regression model that includes treatment arm, stratification variable and baseline measure as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24
Percentage of ParticipantsCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 2438.7 (32.3 to 45.0)25.3 (18.4 to 32.3)———————
Statistical analysis
  • Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) vs Placebo + Methotrexate (Cohort 1, IP) · Regression, Logistic · p = 0.0112
SecondaryPercentage of Participants in SDAI Remission at Week 52

Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in SDAI Remission at Week 52
Percentage of participantsCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Percentage of Participants in SDAI Remission at Week 5229.8 (23.8 to 35.8)15.3 (9.6 to 21.1)———————
Statistical analysis
  • Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) vs Placebo + Methotrexate (Cohort 1, IP) · Regression, Logistic · p = 0.0021
SecondaryMean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52

The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage. The mean change from baseline in TSS using modified Sharp/van der Heijide scores was assessed using a rank-based nonparametric ANCOVA model.

Time frame:
Week 52
Reported as:
Mean · Total Sharp Score
Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52
Total Sharp ScoreCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 520.53 ± 2.2792.52 ± 6.205———————
Statistical analysis
  • Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) vs Placebo + Methotrexate (Cohort 1, IP) · rank-based ANCOVA · p = < 0.0001
SecondaryPercentage of Participants in Boolean Remission at Week 52

Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale). Logistic regression was used for this endpoint.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in Boolean Remission at Week 52
Percentage of participantsCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Percentage of Participants in Boolean Remission at Week 5221.5 (17.7 to 25.3)11.6 (8.0 to 15.2)———————
Statistical analysis
  • Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) vs Placebo + Methotrexate (Cohort 1, IP) · Regression, Logistic · p = 0.0006

Adverse events

Collected over approximately 54 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)1/451 (0.2%)32/451 (7.1%)237/451 (52.5%)
Placebo + Methotrexate (Cohort 1, IP)1/301 (0.3%)9/301 (3%)152/301 (50.5%)
Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)0/242 (0%)23/242 (9.5%)123/242 (50.8%)
Abatacept + Methotrexate (De-Escalation Period)0/50 (0%)3/50 (6%)12/50 (24%)
Abatacept (End of Week) + Methotrexate (De-Escalation Period)1/50 (2%)3/50 (6%)22/50 (44%)
Abatacept Monotherapy (De-Escalation Period)0/47 (0%)0/47 (0%)10/47 (21.3%)
Methotrexate Monotherapy (De-Escalation Period)0/37 (0%)0/37 (0%)16/37 (43.2%)
Abatacept + Methotrexate (Open Label Period)1/685 (0.1%)40/685 (5.8%)230/685 (33.6%)
Abatacept + Methotrexate (Open Label Extension Period)0/120 (0%)0/120 (0%)15/120 (12.5%)
Most frequent serious events
Showing 10 of 103
Most frequent serious events
EventCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
Pancreatitis acuteGastrointestinal disorders0/4510/3010/2420/501/500/470/370/6850/120
PyrexiaGeneral disorders0/4510/3010/2420/501/500/470/370/6850/120
CholelithiasisHepatobiliary disorders0/4510/3010/2421/500/500/470/371/6850/120
Infectious mononucleosisInfections and infestations0/4510/3010/2420/501/500/470/370/6850/120
PneumoniaInfections and infestations2/4512/3011/2420/501/500/470/372/6850/120
Benign prostatic hyperplasiaReproductive system and breast disorders0/4510/3010/2421/500/500/470/370/6850/120
PneumothoraxRespiratory, thoracic and mediastinal disorders0/4510/3011/2420/501/500/470/370/6850/120
Knee operationSurgical and medical procedures0/4510/3010/2421/500/500/470/370/6850/120
Cholecystitis acuteHepatobiliary disorders1/4510/3012/2420/500/500/470/371/6850/120
Urinary tract infectionInfections and infestations2/4511/3011/2420/500/500/470/370/6850/120
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCombination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Abatacept + Methotrexate (De-Escalation Period)Abatacept (End of Week) + Methotrexate (De-Escalation Period)Abatacept Monotherapy (De-Escalation Period)Methotrexate Monotherapy (De-Escalation Period)Abatacept + Methotrexate (Open Label Period)Abatacept + Methotrexate (Open Label Extension Period)
NasopharyngitisInfections and infestations63/45143/30136/2422/506/504/475/3759/6856/120
BronchitisInfections and infestations19/45112/30116/2423/506/501/470/3724/6851/120
NauseaGastrointestinal disorders42/45124/30122/2421/502/500/471/3723/6850/120
Upper respiratory tract infectionInfections and infestations24/45116/30118/2421/502/501/473/3728/6853/120
HeadacheNervous system disorders31/45121/3018/2420/501/501/471/3720/6850/120
GastroenteritisInfections and infestations13/4519/30110/2420/503/501/472/3713/6851/120
Aspartate aminotransferase increasedInvestigations14/45110/3019/2423/500/500/470/3711/6850/120
HypertensionVascular disorders11/4518/3015/2420/503/500/470/374/6850/120
StomatitisGastrointestinal disorders27/4518/3011/2420/501/502/472/3721/6852/120
AnaemiaBlood and lymphatic system disorders12/45118/3014/2421/501/500/471/3710/6851/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Mean48.9 ± 12.7448.8 ± 13.9950.0 ± 12.9149.1 ± 13.17
Sex: Female, Male
Sex: Female, Male(Participants)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Female349243189781
Male1025853213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
WHITE315209174698
BLACK/AFRICAN AMERICAN2016743
AMERICAN INDIAN/ALASKA NATIVE0314
ASIAN775211140
RACE - OTHER/ NOT REPORTED392149109
HISPANIC OR LATINO85922
NOT HISPANIC OR LATINO433732112
ETHNICITY - NOT REPORTED400259201860
MODIFIED SHARP/VAN DER HEIJDE TOTAL SCORE (mTSS)
MODIFIED SHARP/VAN DER HEIJDE TOTAL SCORE (mTSS)(Scores on a scale)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Mean9.82 ± 16.34212.99 ± 19.769—11.08 ± 17.839
Tender Joints - 28
Tender Joints - 28(Joint Count)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Mean13.2 ± 6.7613.7 ± 6.77—13.4 ± 6.76
Swollen Joints - 28
Swollen Joints - 28(Joint Count)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Mean10.0 ± 5.7110.7 ± 5.85—10.3 ± 5.77
Subject global assessment of disease activity
Subject global assessment of disease activity(mm)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Mean65.7 ± 22.762.7 ± 24.05—64.5 ± 23.28
Physician global assessment of disease activity
Physician global assessment of disease activity(mm)Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP)Placebo + Methotrexate (Cohort 1, IP)Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP)Total
Mean65.1 ± 18.4866.1 ± 19.75—65.5 ± 18.99

3 further baseline measures are reported on the registry.

08

Study locations

201 sites
  • Rheumatology Associates Of North Alabama, P.C.
    Huntsville, Alabama 35801, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Mesa, Arizona 85210, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Phoenix, Arizona 85032, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Phoenix, Arizona 85037, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Sun City, Arizona 85351, United States
  • CHI St. Vincent Medical Group Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Arkansas Primary Care Clinic
    Little Rock, Arkansas 72204, United States
  • St. Joseph Heritage Medical Group
    Fullerton, California 92835, United States
  • Healthcare Partners Medical Group
    Huntington Beach, California 92646, United States
  • Valerius Medical Group and Research Center
    Los Alamitos, California 90720, United States
  • Inland Rheumatology Clinical Trials Inc.
    Upland, California 91786, United States
  • Joao Nascimento
    Bridgeport, Connecticut 06606, United States
  • Rheumatology Associates Of Central Florida, P.A.
    Orlando, Florida 32806, United States
  • Tampa Medical Group, Pa
    Tampa, Florida 33614, United States
  • Coeur D'Alene Arthrit Clin
    Coeur d'Alene, Idaho 83814, United States
  • Arthritis And Diabetes Clinic
    Monroe, Louisiana 71203, United States
  • Klein And Associates, M.D., Pa
    Hagerstown, Maryland 21740, United States
  • St. Paul Rheumatology, P.A.
    Eagan, Minnesota 55121, United States
  • Arthritis Consultants
    Saint Louis, Missouri 63141, United States
  • Physician Research Collaboration, Llc
    Lincoln, Nebraska 68516, United States
  • Arthritis And Osteoporosis Associates, Pa
    Freehold, New Jersey 07728, United States
  • Physicians Research Center, Llc
    Toms River, New Jersey 08755, United States
  • Albuquerque Center For Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Hospital For Special Surgery
    New York, New York 10021-4892, United States
  • Local Institution
    Hickory, North Carolina 28601, United States
  • Pmg Research Of Salisbury
    Salisbury, North Carolina 28144, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Pmg Research Of Wilmington Llc
    Wilmington, North Carolina 28401, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Ctr For Arthritis Therapy And Research, Inc.
    Tulsa, Oklahoma 74104, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • The Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Clinical Research Center Of Reading, Llp
    Wyomissing, Pennsylvania 19610, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Houston Institute For Clinical Research
    Houston, Texas 77074, United States
  • Arthritis Clinic Of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Spectrum Medical, Inc.
    Danville, Virginia 24541, United States
  • Arthritis Northwest
    Spokane, Washington 99204, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Organizacion Medica De Investigacion S.A. (Omi)
    Capital Federal, Buenos Aires 1015, Argentina
  • Local Institution
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Hospital General De Agudos J.M. Ramos Mejia
    Ciudad Autonoma De Buenos Aire, Buenos Aires 1221, Argentina
  • Framingham Centro Medico
    La Plata, Buenos Aires 1902, Argentina
  • Instituto de Asistencia Reumatologica Integral
    San Fernando, Buenos Aires 1646, Argentina
  • Caici
    Rosario, Santa FE 2000, Argentina
  • Instituto De Rehabilitacion Psicofisica
    Buenos Aires, 1428, Argentina
  • Centro Consultora Integral de Salud SRL
    Cordoba, 5004, Argentina
  • Hospital Privado-Centro Medico De Cordoba S.A.
    Cordoba, 5016, Argentina
  • Centro De Investigaciones Reumatologicas
    Tucuman, 4000, Argentina
  • Centro Medico Privado De Reumatologia
    Tucuman, 4000, Argentina
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Southport, Queensland 4215, Australia
  • Local Institution
    Hobart, Tasmania 7000, Australia
  • Local Institution
    Camberwell, Victoria 3124, Australia
  • Local Institution
    Coffs Harbour, 2450, Australia
  • Rheuma Zentrum Favoriten
    Wien, 1100, Austria
  • Local Institution
    Juiz De Fora, Minas Gerais 36010-570, Brazil
  • Local Institution
    Varginha, Minas Gerais 37006-710, Brazil
  • Local Institution
    Curitiba, Parana 80030-110, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90480-000, Brazil
  • Local Institution
    Santo Andre, SAO Paulo 09060-870, Brazil
  • Local Institution
    Sao Paulo, 01228-200, Brazil
  • Local Institution
    Sao Paulo, 04032-060, Brazil
  • Local Institution
    Sao Paulo, 04266-010, Brazil
  • Local Institution
    Winnipeg, Manitoba R3A 1M3, Canada
  • Local Institution
    Montreal, Quebec H2L 1S6, Canada
  • Centre De Recherche Musculo-Squelettique
    Trois-rivieres, Quebec G8Z 1Y2, Canada
  • Local Institution
    Saskatchewan, S7K 0H6, Canada
  • Centro Medico de Reumatologia Limitada
    Temuco, Araucania 4790928, Chile
  • Centro De Estudios Reumatologicos
    Santiago De Chile, Metropolitana 7501126, Chile
  • Someal
    Santiago, Metropolitana 7510586, Chile
  • Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S
    Bogota, Colombia
  • Fundacion Instituto de Reumatologia Fernando Chalem
    Bogota, Colombia
  • Clinica de Artritis Temprana
    Cali, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, MEDELLIN, Colombia
  • Oddeleni klinicke farmakologie
    Plzen-Bory, 305 99, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • MEDICAL PLUS, s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • PV Medical Services, s.r.o.
    Zlin, 760 01, Czechia
  • Local Institution
    Hyvinkaa, 05800, Finland
  • Local Institution
    Kuopio, 70110, Finland
  • Local Institution
    Lyon Cedex 03, 69437, France
  • Local Institution
    Orleans cedex 2, 45067, France
  • Local Institution
    Poitiers, 86021, France
  • Local Institution
    Toulouse cedex 9, 31059, France
  • Rheumapraxis Dr. Kurthen
    Aachen, 52064, Germany
  • Charite Campus Mitte
    Berlin, 10117, Germany
  • Rheumatologische Schwerpunktpraxis Dr. Zinke
    Berlin, 13055, Germany
  • Immanuel Krankenhaus Berlin/Rheumaklinik Berlin Buch
    Berlin, 13125, Germany
  • Schlosspark-Klinik
    Berlin, 14059, Germany
  • Schwerpunktpraxis fuer Rheumatologie an den Kreiskliniken
    Burghausen, 84489, Germany
  • Klinikum Der Albrecht-Ludwigs-Universitat
    Freiburg, 79106, Germany
  • MVZ Rheuma
    Hamburg, 20095, Germany
  • Hamburger Rheuma Forschungszentrum
    Hamburg, 22391, Germany
  • Gemeinschaftspraxis Drs. von Hinueber u Demary
    Hildesheim, 31134, Germany
  • Rheumatologie In Wuermtal
    Planegg, 82152, Germany
  • Praxis Dr. Walter
    Rendsburg, 24768, Germany

Showing the first 100 of 201 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jan 2017, 16 months.

Results were first posted in Apr 2019, 2 years 2 months after primary completion. A results delay was requested in Dec 2017.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2015
First posted
Jul 21, 2015
StartActual
Sep 3, 2015
Primary completionActual
Jan 16, 2017
CompletionActual
Mar 19, 2020
Results delay requested
Dec 6, 2017
Results first posted
Apr 8, 2019
Last update
Jun 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02504268
Responsible party
Sponsor
First posted
Jul 21, 2015
Start date
Sep 3, 2015
Primary completion
Jan 16, 2017
Completion
Mar 19, 2020
Results posted
Apr 8, 2019
Last update
Jun 28, 2021

Study contacts

Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Methotrexate

Start the discussion